Dronedarone is a new antiarrhythmic drug that is being developed for the treatment of patients with atrial fibrillation.
Dronedarone is a new multichannel blocker for atrial fibrillation (AF) previously demonstrated to have both rhythm and rate control properties in paroxysmal and persistent AF. The Efficacy and safety of dRonedArone for The cOntrol of ventricular rate during atrial fibrillation (ERATO) trial assessed the efficacy of dronedarone in the control of ventricular rate in patients with permanent AF, when added to standard therapy.
Thromboembolic Risk Reduction
Validation of Clinical Classification Schemes for Predicting Stroke. Patients who have artial fibrillation (AF) have an increased risk of stroke, but their absolute rate of stroke depends on age and comorbid conditions.
Refining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor-Based Approach : The Euro Heart Survey on Atrial Fibrillation
A Novel User-Friendly Score (HAS-BLED) To Assess 1-Year Risk of Major Bleeding in Patients With Atrial Fibrillation : The Euro Heart Survey. Despite extensive use of oral anticoagulation (OAC) in patients with atrial fibrillation (AF) and the increased bleeding risk associated with such OAC use, no handy quantification tool for assessing this risk exists.
Dabigatran versus Warfarin in Patients with Atrial Fibrillation. Warfarin reduces the risk of stroke in patients with atrial fibrillation but increases the risk of hemorrhage and is difficult to use. Dabigatran is a new oral direct throm- bin inhibitor.
Apixaban in Patients with Atrial Fibrillation. Vitamin K antagonists have been shown to prevent stroke in patients with atrial fibrillation. However, many patients are not suitable candidates for or are unwilling to receive vitamin K antagonist therapy, and these patients have a high risk of stroke. Apixaban, a novel factor Xa inhibitor, may be an alternative treatment for such patients.
Atrial fibrillation (AF) is a condition in which the upper chambers of the heart (atria) beat in a very rapid and irregular manner causing the lower chambers (ventricles) to also beat quickly and irregularly. It can be related to high blood pressure, previous heart attacks, heart valve disease or other heart disease, but in many patients no obvious cause can be found.
All patients with atrial fibrillation should have a complete history and physical examination, electrocardiogram, echocardiogram, basic laboratory investigations. Details are highlighted in Table 1. (Strong Recommendation; Low Quality Evidence)
HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: Recommendations for Personnel, Policy, Procedures and Follow-Up
AF from PVs
SPONTANEOUS INITIATION OF ATRIAL FIBRILLATION BY ECTOPIC BEATS ORIGINATING IN THE PULMONARY VEINS. Atrial fibrillation, the most common sustained cardiac arrhythmia and a major cause of stroke, results from simultaneous reentrant wavelets. Its spontaneous initiation has not been studied.
PVA for patients
Atrial fibrillation (AF) is a heart rhythm disorder with rapid, irregular, and chaotic electrical activity in the atria (Figure). The atrial electrical sig- nals bombard the AV node, and some pass through the AV node to the ven- tricles, producing a rapid, irregular rate and often causing symptoms of palpi- tations, shortness of breath, or fatigue. AF affects more than 2 million people in the United States alone; it is seen progressively more frequently as a per- son ages.
PVA five year fu
Catheter ablation that predominantly targets pulmonary veins (PVs) is well established as a treatment option for patients with symptomatic drug refractory atrial fibrillation (AF), with a steady growth in the number of interventions performed over the past decade (1). Although recent con- sensus guidelines emphasize the important need for long- term result reporting (1), most studies have limited follow-up to 1 year or less, with few outcome data beyond 3 years.
Worldwide survey PVA
Worldwide Survey on the Methods, Efficacy, and Safety of Catheter Ablation for Human Atrial Fibrillation. Since its introduction into clinical practice,1,2 catheter ablation (CA) aimed at cure of atrial fibrillation (AF) has become increasingly prevalent.